TUBACEX announces consolidated results and ends 2019 with an EBITDA of €67.1 million

2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.

TUBACEX consolidates growth increasing its backlog

TUBACEX order intake continues to grow month by month and it now stands at 40% above the average for recent years. TUBACEX is involved in the final negotiation stages of large projects expected to be closed in the short term, which will represent an unprecedented...